Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net earnings	$ 128,286	$ 128,109
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	16,924	16,133
Net (gain) loss on sale of long-lived assets	611	0
(Gain) loss on deconsolidation	(3,411)	(2,237)
Share-based compensation	4,964	3,966
Excess tax benefit from share-based compensation	(2,090)	(1,210)
Deferred income taxes	17,872	19,329
Equity in earnings of unconsolidated affiliates, net	(1,303)	(1,098)
Increase (decrease) in cash and cash equivalents, net of effects of acquisitions and dispositions, due to changes in:
Accounts receivable, net	(5,979)	(5,221)
Supplies inventory	(7)	(320)
Prepaid and other current assets	(2,310)	(2,057)
Accounts payable	(2,397)	(2,351)
Accrued expenses and other liabilities	769	(2,155)
Other, net	1,652	1,662
Net cash flows provided by operating activities	153,581	152,550
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	(24,437)	(18,346)
Acquisition of property and equipment	(16,075)	(12,472)
Proceeds from sale of interests in surgery centers	2,092	0
Other	(1,381)	55
Net cash flows used in investing activities	(39,801)	(30,763)
Cash flows from financing activities:
Proceeds from long-term borrowings	74,246	70,922
Repayment on long-term borrowings	(102,326)	(96,222)
Distributions to noncontrolling interests	(92,010)	(91,526)
Proceeds from issuance of common stock upon exercise of stock options	1,646	13,728
Repurchase of common stock	(2,857)	(26,164)
Capital contributions and ownership transactions by noncontrolling interests	(498)	936
Excess tax benefit from share-based compensation	2,090	1,210
Financing cost incurred	0	(1,146)
Net cash flows provided by (used in) financing activities	(119,709)	(128,262)
Net increase (decrease) in cash and cash equivalents	(5,929)	(6,475)
Cash and cash equivalents, beginning of period	50,840	46,398
Cash and cash equivalents, end of period	$ 44,911	$ 39,923